F10 and hemophilia A: The licensing of emicizumab, a humanized anti-FIXa/FX bispecific antibody that acts as an FVIII-mimicking agent, has revolutionized the management of patients with hemophilia A with inhibitors, thanks to its mechanism of action independent of FVIII.